DarbeLus

A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes

What's the purpose of the trial?

This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in SF3B1 wild type, lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
60
Last Updated

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Darbepoetin Alfa is a bone marrow stimulant used to treat anemia caused by kidney failure or chemotherapy.
  • Luspatercept is an agent that helps your bone marrow finish making red blood cells that have started to form.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Luspatercept + Darbepoetin

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.